Urology
Volume 75, Issue 5 , Pages 1004-1008 , May 2010

Reduction in Patient-reported Acute Morbidity in Prostate Cancer Patients Treated With 81-Gy Intensity-modulated Radiotherapy Using Reduced Planning Target Volume Margins and Electromagnetic Tracking: Assessing the Impact of Margin Reduction Study

Presented at the 51st annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), November 1-4, 2009.

  • Howard M. Sandler

      Affiliations

    • Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California
    • Corresponding Author InformationReprint requests: Howard M. Sandler, M.D., M.S., Department of Radiation Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048
    • ,
  • Ping-Yu Liu

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Rodney L. Dunn

      Affiliations

    • Department of Urology, University of Michigan, Ann Arbor, Michigan
    • ,
  • David C. Khan

      Affiliations

    • 21st Century Oncology, Santa Monica, California
    • ,
  • Scott E. Tropper

      Affiliations

    • 21st Century Oncology, Scottsdale, Arizona
    • ,
  • Martin G. Sanda

      Affiliations

    • Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts
    • ,
  • Constantine A. Mantz

      Affiliations

    • 21st Century Oncology, Cape Coral, Florida

Received 24 September 2009 ,Accepted 25 October 2009.

References 

  1. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA. 2005;294:1233–1239
  2. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  3. Peeters ST, Heemsbergan WD, Koper PC, et al. Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990–1996
  4. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomized controlled trial. Lancet Oncol. 2007;8:475–487
  5. Gauthier I, Carrier JF, Béliveau-Nadeau D, et al. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment. Int J Radiat Oncol Biol Phys. 2009;74:1128–1133
  6. Huang SH, Catton C, Jezioranski J, et al. The effect of changing technique, dose, and PTV margin on therapeutic ratio during prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2008;71:1057–1064
  7. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905
  8. Kupelian P, Willoughby T, Mahadevan A, et al. Multi-institutional clinical experience with the Calypso system in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1088–1098
  9. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261
  10. Scoring instructions for the expanded prostate cancer index composite (EPIC): University of Michigan. http://roadrunner.cancer.med.umich.edu/epic/EPIC-Scoring-2.2002.pdfAccessed August 12, 2009
  11. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582–592
  12. Litzenberg DW, Balter JM, Hadley SW, et al. Influence of intrafraction motion on margins for prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65:548–553
  13. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet. 1999;353:267–272
  14. Heemsbergen WD, Peeters ST, Koper PC, et al. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys. 2006;66:3–10
  15. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124–1129

 Supported by Calypso Medical Technologies, Inc. and NIH R01CA 95662.

 P-Y Liu, and R.L. Dunn, are paid statistical consultants for Calypso Medical Technologies, Inc.

PII: S0090-4295(09)03007-6

doi: 10.1016/j.urology.2009.10.072

Urology
Volume 75, Issue 5 , Pages 1004-1008 , May 2010

Article Tools